Evaluation of the remission of lupus nephritis with induction immunosuppressive treatment in an Ecuadorian population.

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/708a9e786c9ef3eee67d24a09ca6bc40.pdf

Abstract Title

First Name *

María José

Last Name *

Cajas

Co-author 1

Jorge Chonata drchonataquinteros@gmail.com Hospital de Especialidades Eugenio Espejo Nefrología Quito

Co-author 2

Washington Osorio dr.osoriowhm@gmail.com Hospital de las Fuerzas Armadas N 1 Nefrología Quito

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect any organ in the body. One of the main complications of this disease is lupus nephritis (LN), which occurs in 50% of patients with SLE. The standard of induction treatment consists of Corticosteroids plus immunosuppressants such as Cyclophosphamide or Mycophenolate Mofetil (MMF). Achieving remission correlates with long-term renal survival.

Methods

A retrospective analytical observational cohort study was carried out at the Eugenio Espejo Specialty Hospital, considering the following data “n” = 185 patients with LN, of which 68 met the inclusion criteria. The selected variables were: sex, ethnicity, age at diagnosis of Systemic lupus erythematosus (SLE) and lupus nephritis (LN), APS antibodies, SLEDAI-2K, HBP, ISN/RPS Class, induction immunosuppressant, clinical remission and reactivation. Descriptive and inferential tests with statistical significance were performed. of p < 0.05 in the SPSS version 25 program.

Results

Conclusions

The efficacy of MMF is comparable to the results of Cyclophosphamide in terms of remission and reactivation in our population.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos